BETHESDA, Md., May 4, 2016 -- The Bladder Cancer Advocacy Network is pleased to announce the appointment of Andrea Maddox-Smith as Chief Executive Officer, effective May 2.
Maddox-Smith is an innovative and energetic leader with extensive experience in non-profit management, program development and fundraising. Prior to joining BCAN, Maddox-Smith served in a variety of leadership roles at the American Diabetes Association for 16 years, most recently as the senior vice president, Eastern division/nationwide mission delivery. In this role, she oversaw all aspects of operations management, new business development, staff management and volunteer recruitment.
"We are thrilled to have Andrea on board," said Diane Zipursky Quale, co-Founder of BCAN. "We know that she will inspire the bladder cancer community and marshal the people and resources necessary to collaboratively implement BCAN's mission and ensure the organization's continued growth and impact."
The new leadership comes at a critical time in the organization's history with the recent introduction of the Bladder Cancer Genomics Consortium. A collaboration with BCAN and major medical institutions, the consortium is designed to increase research to improve outcomes for bladder cancer patients.
"I strive to create a sense of urgency around this disease that would allow every newly diagnosed bladder cancer patient access to BCAN resources," said Maddox-Smith. "I am excited to bring a progressive and results oriented approach and vision to the organization by collaborating with the many volunteers, researchers, clinicians and members."
About the Bladder Cancer Advocacy Network
The Bladder Cancer Advocacy Network's mission is to increase public awareness about bladder cancer, advance bladder cancer research, and provide educational and support services for the bladder cancer community. BCAN serves as the leading voice for bladder cancer in the U.S., providing resources to not only those diagnosed with the disease but their families, caregivers and the medical community united in support of people impacted by the disease. The organization is setting the agenda for bladder cancer by promoting and funding collaborative and cutting-edge research programs and providing critical patient support and education services. BCAN works collaboratively with the medical and research professionals dedicated to the prevention, diagnosis, and treatment of bladder cancer, and empowers the patient community by allowing them to share experiences with others and to participate in building awareness of the need for a cure. For more information go to www.bcan.org or call 1-888-901-BCAN (2226).
CONTACT: Natalie Bennett
Email: [email protected]
Phone: 301.215.9099 ext 202


OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 



